Apricell Biotechnology is an early-stage company with a focus on developing life science-based technologies interfacing with biomaterials, and tumor biology. In order to address the current challenges in cancer chemo/immunotherapy with bioengineering solutions, Apricell was founded to provide a breakthrough in developing a "tumoroid on-a-chip" technology for pursuing the goal of pre-clinical drug efficacy testing in drug development process. We are truly passionate about providing patient-driven preclinical models through which the most precise treatment could be prescribed for individual cancer patients.